US FDA approves Sarepta's gene therapy for rare muscular dystrophy in some kids
By Leroy Leo and Aditya Samal (Reuters) -The U.S. Food and Drug Administration on Thursday granted accelerated approval to Sarepta
1970-01-01 08:00
Families facing rare muscle disease are pushing for an experimental gene therapy, but the FDA is skeptical
SRP-9001, an experimental gene therapy that aims to slow or stop the progression of Duchenne muscular dystrophy, is being considered for accelerated approval by the FDA.
1970-01-01 08:00